Christopher R. Reidy
Thanks, Vince, everyone. and morning, good
Moving the I'll our EPS second results on key highlights. to as as X, slide financial quarter and revenue review well
performance As BD is strong. new as Vince our mentioned, the
Second three was favorable expected driven all across across flu a grew and and ahead our expectations three revenues strong basis, On segments, strength a stronger all by quarter season currency. driven foreign revenue segments. than was growth X.X%, growth by comparable of
approximately second quarter the from change, included revenue results lowered Our U.S. basis growth impact XX the dispensing by adverse which points.
quarter and quarter the revenues comparison headwinds the change the second points were revenue in annualized with year-over-year approximately Offsetting change. the change, company quarter total the flu mentioned, dispensing that the basis As to U.S. the XX growth. this we final Vince have related dispensing issue accordingly, contributed was from to
Pricing quarter, in both Excluding I includes Adjusted growth you was about a quarter the the This on our of BD currency in $X.XX this, segment expected. underlying dispensing basis points XXX Adjusting or through the X.X% a impact expectations. grew as provide in by more Bard both results on of in EPS line of geography. also the by teens. these neutral from second color XX the take and approximately driven basis. neutral with when U.S. currency businesses. moment XX.X% legacy the of EPS I grew revenues points will revenue strong was growth in performance Growth items, and change adverse for low X.X%. the basis declined
U.S. In weakening due of quarter addition, FX year-over-year the was a dollar. to this the tailwind
with earlier, very mentioned are as first pleased Vince combined our entity. we quarter As a
momentum reflects year. second half quarter outlook revenue of second current our the the continued Our and outperformance over
end of revenue the result, raising high are a range. As our we guidance to previous our
foreign currency. EPS guidance more a to also from are We adjusted our benefit reflect favorable raising
maintaining my detailed I'll are incremental more guidance, expenses of EPS the provide in commentary year. our some later as remarks. guidance currency-neutral half anticipate We we the second in
declined times, and driven of million of also Before March we to I as out $XXX on, move gross of in X.X ratio point by to that our the XX, pay-down growth leverage debt. want EBITDA
target years. on X deleverage commitment are below times over with We to three to our
review growth devices. basis was increased Growth from X.X%. segment quarter. headwind from Revenues currency-neutral change. Delivery of BD the Medication vascular prefilled the of grew of X.X% by was in MDS slide emerging driven or in well revenues in that U.S. approximately driven the Medication which Diabetes basis the international as timing headwind for other in Solutions or infusion. and aided by was devices. market Care care, our growth MMS for customers, on points approximately quarter second initially our Systems, in This and grew had access large to strength incremental Medical our Care reflects Solutions includes X.X%. delivery X.X%, a and by drug MMS revenues Underlying Hypak growth prior in in year. XXX Moving Revenues U.S. grew points anticipated we third comparable Management comparison impacted favorable also the biotech demand second growth a by the growth dispensing pen needles basis. the XXX markets grew flush and dispensing revenue revenues in reflects U.S. a Diabetes by revenue U.S. ES growth the I'll by In that strength driven to which pharmaceutical as change. quarter. adoption Pharmaceutical X.X% was X, in includes tenders revenue Revenue on Pyxis of a the in vascular strong prefillable
Life Turning to slide and X BD Sciences the segment.
Kiestra and revenues by Sciences aided points contributed Systems driven to increased XXX in Revenue continued and performance an in the in MAX and growth strength in our by Revenues in in estimated contributed BD stronger X.X%. the a Sciences of molecular Life was last Performance microbiology the basis to flu season offset to by strong growth revenue XX.X% driven Life growth. basis, core year-to-date was growth approximately flu Second On timing grew basis X.X%. year points which by the in Systems, U.S. strong quarter was platform, Biosciences comparison of quarter. a installations partially Diagnostic Diagnostic XXX
grew revenues the reagents. analyzer, to growth by favorable our quarter. X.X% research aided which the prior of contributed points as quarter. XXX impact strength flu reflects In in basis tough research of was growth and year. comparison the production instruments, This Biosciences season issue the Growth and newer a quarter. FACSMelody a Preanalytical as the one resolved growth comparison well such in product the X% continued over the our a lines, in Diagnostic to to Systems year addition, the of reflects Systems also prior FACSymphony in during in was as
turning the Now and to XX BD Interventional slide segment.
drug-coated quarter strong LIFESTREAM and and quarter were in quarter. quarter. growth our in Revenues Second the that AV Peripheral Surgery hernia in growth indication, particularly our international management Surgery strong also in portfolio, the business offset impacted This of points. on a by Critical driven international that the in our launched balloons of strength revenues biopsy May products. as urology orders non-acute leading first in in as XX by X.X%. prevention, by products, grew Intervention in the second XX.X% Urology Growth in from hold quarter. X.X% increased global China, quarter reflects basis growth in in platform strong infection driven continued diverse Growth Care acute partially was XXXX. revenues well in continued capital growth stents from adversely benefited the by X.X% growth and timing to in our the reflects Progel including approximately in temperature the Performance grew
walk strength slide driven for you currency headwind U.S. U.S. of impact the the dispensing from in an second through Growth X% U.S. points geographic by quarter quarter second multiple the the change. a on basis. XX, includes and I'll flu Moving revenues to the businesses neutral revenues basis was estimated our grew in which of XXX season. across comparable, the
Systems by Medication BD growth the Revenues Biosciences mentioned reflects U.S. issue was one U.S., previously in Pharmaceutical BD Delivery Systems Sciences of in Life the units the results were Systems and adversely segment Within Diagnostic units. and the segment our lines. strength impacted units. the production Preanalytical the product Medical driven by Solutions in the in in
BD the three businesses. was U.S., the in across segment all Within driven performance by Interventional growth
Markets XX revenues as Biosciences Care, was of Europe strength discussed, strength and estimated across dispensing basis the to and Developed unit. by the in second quarter U.S. in was Markets Developed in quarter. Life Medical, strong Sciences from change second grew Critical performance the grew and X.X% driven the Systems Growth an Urology including international, Interventional on points. the in Growth in Surgery, and Diagnostics by in previously broad X.X% Moving headwind driven segments. U.S.
revenues and America as by reflects strong EMA systems infusion markets strength Double Care XX.X%. in grew research Delivery also by as double performance and segments. emerging and with quarter across in grew Solutions previously XX.X%, across was the Diagnostic and grew Interventional disposables well the Biosciences Second growth all across revenue Revenues digits China driven and in tender three microbiology reagents Revenues in Latin Medication instruments timing Diabetes digit discussed. growth driven segment. high-single core digit as
XX Turning our to income results. which highlights slide statement recaps neutral second the quarter and currency
impact were the negative discussed, XX expectations basis ahead including points X.X% As from our approximately change. quarter U.S. of growing in the revenues dispensing
which SSG&A revenue R&D SSG&A quarter higher invest starting P&L key our the were continued to revenue reflects I'll profit. a as gross fiscal the into Both R&D XX.X% spending quarter X.X% percentage a in percentage year bottom of in gross the Gross was later innovation. which reflects the year-over-year. down outperformance increased a Moving with that profit on revenues and additional programs second reflect profit and commitment few some our of provide details SSG&A XX.X% from in in was just profile. as accelerated Bard's on line. of a moment. spend offset
basis year in BD. XX.X% in the points XXX Operating is was quarter our guidance with rate reflecting tax new P&L margins increased as leverage Our the which full line strong range.
change. in as million diluted is result dilutive quarter. shares versus the on our outstanding SSG&A our quarter accelerate the offset strong than a growth more more as additional dispensing and share R&D dividends impact EPS quarter, Adjusting EPS excluded adjusted points earnings neutral teens. neutral low the by and previously to a EPS to discussed. in FX the shares preferred preferred basis. dispensing decision of was $XX of to operating The change, U.S. a the and were currency adjusted were As is expectations investments XX.X% from ahead Earnings from are per for and impact paid of of shares the revenue basis $X.XX expected, Both U.S. the in dividend favorable year, the X.X% approximately XXX In due preferred income the negative we preferred include the or growth partially which increase prior calculation. currency in
we These and improvement from basis, On take grew our and the R&D U.S. operating margin slide previously partially Bard's point basis points This in XX offset fiscal over operating basis and slides, was is profit Currency the basis to significant second strong the basis were quarter. improved gross XXX like XX the had change, XX.X% last margin turning a Now to well increase margins margin in through points. mix. Gross addition points gross to quarter. basis of and in out profile synergies while year you reflects continuous partially second gross basis XXX that XXX points robust inclusion in years. points performance of SSG&A profit deliver margin this to margin more XXX I'll pricing. are as expect of our basis driven XXX guidance points This several the margin was of basis and by profit margin a of positive fiscal gross discussing which gross a the impact next margin. profit margins, but combination by items to positive Currency discussed. offset of had a the dispensing improvement expansion the points the to as over favorable on materials quarter. quarter. headwind continue Operating points impact on I'd our a XX three expansion a initiatives, XXXX by XX as cost raw we underlying in margin of approximately for
fiscal year on slide XXXX Moving our to XX revenue and full guidance.
dispensing from Puerto and the to from in XXXX. December X% that impact in Rico the strong excluding underlying X% of growth As of represents on the Hurricane quarter This Bard the for growth Maria X.X% impact estimated change currency-neutral XX, previous the we total a X.X% are previously range. is raising comparable discussed, to company high-end our which guidance to revenue basis our U.S. ended
based be outlook, expect performance higher anticipated. maintaining While than ranges revenue our on previously segment and and in we strong our Interventional to Medical those year-to-date we guidance ranges, are current
As also first segment a the reminder, quarter our Hurricane impact Interventional excludes from guidance Maria.
our are stronger a of the guidance growth than Sciences Life our as increasing expected X% segment result X% to primarily We season. for to flu
to We in continue revenue strength driven both expect markets. be and emerging developed by all growth recent segments launches to three across product and
the developed revenue impact estimated market excluding or reflects basis change X% X.X% guidance XXXX in growth America. to Our increased to dispensing in in X% the around of driven emerging the EMA a from around we XX point X.X% and low-double diversified and to hurricane in fiscal mid-teens In Latin and growth by Rico. growth with base continue digit strength markets, Puerto expect U.S. China
slide and full EPS of are XXXX There to that on fiscal our per impact earnings XX parts XXXX. in Moving guidance. number moving a fiscal share
For chart adjusted and ensure like to to provide of $XX.XX modeling EPS growth reflected income the guidance. dispensing on headwinds of EPS of an currency-neutral I'd call, to or we X% the February basis X% with we on provided expected left color of to growth This XX% strong purposes Starting to the guidance consistency, in from earnings our approximately more on on XX% $XX. the driven operating underlying XX% by change. U.S. excluding half
Assuming would approximately of expected an tailwind currency at that rates EPS in fiscal to growth expected foreign time X.X% provide XX% place resulting we in in XXXX currency a XX%.
in Our as well costs. PAS half current updated these as of FX. our well increased more increases second material costs and trials performance investments offsetting occurring that as anticipate the outlook the clinical year favorable guidance additional as reflects are associated in we in year-to-date systems with quality our strong and our Partially revenue
in, XXXX. the XX.X%. to a in XX% joint in guidance currency-neutral $X.XX In continue addition, to a which growth we to $X.XX the to our in Vyaire range represents adjusted this basis On All increase expect XX% $XX.XX results $XX.XX of adjusted a venture pressure. EPS EPS results of of to growth fiscal of divestiture approximately approximately
dollar FX $X.XX, Even full euro assume of a at year unchanged. rate remains with outlook $X.XX. exchange Our euro our to assumptions today's
expect to in fiscal accretion deliver in and XXXX. digit fiscal to continue year year accretion We XXXX low-single digit high-single
We synergies XXXX. are to fiscal fully committed realizing year cost annualized exit million $XXX we in as
our you the for the expectations like slide guidance Now balance of through walk full year XX, turning to fiscal I'd XXXX. to
XX% fiscal for includes results guidance of the beginning of an reminder, January year which improvement of a of basis this which the the a Bard XXX between our is and about XXXX, expected reported a tailwind of XXX be basis, currency XX.X% total quarter. second growth points of guidance is to basis tailwinds. On revenue points, prior about from reflects X, our As as
count For anticipate fully fiscal to XXX adjusted shares. we continue be to year our approximately XXXX, share million average diluted
point would outstanding. excluded deduction shares the purposes, the For I income the preferred out modeling net like diluted are million adjusted of of that the And reflects approximately dividends. shares to $XXX preferred from
Beyond year on we February Bard highly guidance revenues other excited we strong both the In fiscal that I'm our businesses BD I'm the have and and from summary, across will beyond. in about all and remained EPS, commitments momentum P&L unchanged. deliver and confident XXXX
who and call with will Now I'd the to portfolio. initiatives you provide key on like to turn over back an product our Vince update
